145 related articles for article (PubMed ID: 33142709)
1. Therapeutic Efficacy of GC1118, a Novel Anti-EGFR Antibody, against Glioblastoma with High EGFR Amplification in Patient-Derived Xenografts.
Lee K; Koo H; Kim Y; Kim D; Son E; Yang H; Lim Y; Hur M; Lee HW; Choi SW; Nam DH
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33142709
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification.
Choi SW; Jung HA; Cho HJ; Kim TM; Park CK; Nam DH; Lee SH
Cancer Med; 2023 Aug; 12(15):15788-15796. PubMed ID: 37537946
[TBL] [Abstract][Full Text] [Related]
3. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
[TBL] [Abstract][Full Text] [Related]
4. GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands.
Lim Y; Yoo J; Kim MS; Hur M; Lee EH; Hur HS; Lee JC; Lee SN; Park TW; Lee K; Chang KH; Kim K; Kang Y; Hong KW; Kim SH; Kim YG; Yoon Y; Nam DH; Yang H; Kim DG; Cho HS; Won J
Mol Cancer Ther; 2016 Feb; 15(2):251-63. PubMed ID: 26586721
[TBL] [Abstract][Full Text] [Related]
5. A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors.
Oh DY; Lee KW; Han SW; Kim JW; Shin JW; Jo SJ; Won J; Hahn S; Lee H; Kim WH; Bang YJ
Oncologist; 2019 Aug; 24(8):1037-e636. PubMed ID: 31164456
[TBL] [Abstract][Full Text] [Related]
6. A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors.
Chung TK; Lee HA; Park SI; Oh DY; Lee KW; Kim JW; Kim JH; Woo A; Lee SJ; Bang YJ; Lee H
Clin Transl Sci; 2021 May; 14(3):990-1001. PubMed ID: 33382918
[TBL] [Abstract][Full Text] [Related]
7. Lycorine inhibits glioblastoma multiforme growth through EGFR suppression.
Shen J; Zhang T; Cheng Z; Zhu N; Wang H; Lin L; Wang Z; Yi H; Hu M
J Exp Clin Cancer Res; 2018 Jul; 37(1):157. PubMed ID: 30016965
[TBL] [Abstract][Full Text] [Related]
8. Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma.
Hicks MJ; Chiuchiolo MJ; Ballon D; Dyke JP; Aronowitz E; Funato K; Tabar V; Havlicek D; Fan F; Sondhi D; Kaminsky SM; Crystal RG
PLoS One; 2016; 11(10):e0162978. PubMed ID: 27711187
[TBL] [Abstract][Full Text] [Related]
9. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme.
Eller JL; Longo SL; Hicklin DJ; Canute GW
Neurosurgery; 2002 Oct; 51(4):1005-13; discussion 1013-4. PubMed ID: 12234411
[TBL] [Abstract][Full Text] [Related]
10. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronic acid-functionalized gelatin hydrogels reveal extracellular matrix signals temper the efficacy of erlotinib against patient-derived glioblastoma specimens.
Pedron S; Wolter GL; Chen JE; Laken SE; Sarkaria JN; Harley BAC
Biomaterials; 2019 Oct; 219():119371. PubMed ID: 31352310
[TBL] [Abstract][Full Text] [Related]
12. EGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patient‑derived xenografts with cetuximab.
Wang X; Fu R; Hu Y; Du H; Li S; Li Z; Liu Y; Li Q; Zhang L; Ji J
Oncol Rep; 2017 Oct; 38(4):2387-2393. PubMed ID: 28849161
[TBL] [Abstract][Full Text] [Related]
13. Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.
Brown KE; Chagoya G; Kwatra SG; Yen T; Keir ST; Cooter M; Hoadley KA; Rasheed A; Lipp ES; Mclendon R; Ali-Osman F; Bigner DD; Sampson JH; Kwatra MM
J Neurochem; 2015 Jun; 133(5):730-8. PubMed ID: 25598002
[TBL] [Abstract][Full Text] [Related]
14. Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures.
Alcaniz J; Winkler L; Dahlmann M; Becker M; Orthmann A; Haybaeck J; Krassnig S; Skofler C; Kratzsch T; Kuhn SA; Jödicke A; Linnebacher M; Fichtner I; Walther W; Hoffmann J
Front Oncol; 2023; 13():1129627. PubMed ID: 37114125
[TBL] [Abstract][Full Text] [Related]
15. Use of a Target-Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of GC1118, an Anti-epidermal Growth Factor Receptor Antibody.
Park WS; Han S; Lee J; Hong T; Won J; Lim Y; Lee K; Byun HY; Yim DS
Basic Clin Pharmacol Toxicol; 2017 Mar; 120(3):243-249. PubMed ID: 27637171
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM.
McKinney A; Lindberg OR; Engler JR; Chen KY; Kumar A; Gong H; Lu KV; Simonds EF; Cloughesy TF; Liau LM; Prados M; Bollen AW; Berger MS; Shieh JTC; James CD; Nicolaides TP; Yong WH; Lai A; Hegi ME; Weiss WA; Phillips JJ
Mol Cancer Ther; 2019 Sep; 18(9):1565-1576. PubMed ID: 31270152
[TBL] [Abstract][Full Text] [Related]
17. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.
Sarkaria JN; Carlson BL; Schroeder MA; Grogan P; Brown PD; Giannini C; Ballman KV; Kitange GJ; Guha A; Pandita A; James CD
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2264-71. PubMed ID: 16609043
[TBL] [Abstract][Full Text] [Related]
18. Amplification of the EGFR gene can be maintained and modulated by variation of EGF concentrations in in vitro models of glioblastoma multiforme.
William D; Mokri P; Lamp N; Linnebacher M; Classen CF; Erbersdobler A; Schneider B
PLoS One; 2017; 12(9):e0185208. PubMed ID: 28934307
[TBL] [Abstract][Full Text] [Related]
19. Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer.
Chen Z; Huang W; Tian T; Zang W; Wang J; Liu Z; Li Z; Lai Y; Jiang Z; Gao J; Shen L
J Hematol Oncol; 2018 Feb; 11(1):20. PubMed ID: 29433585
[TBL] [Abstract][Full Text] [Related]
20. A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification.
Zhu H; Wang C; Wang J; Chen D; Deng J; Deng J; Fan J; Badakhshi H; Huang X; Zhang L; Cai J; Guo S; Qian W; Nie Y; Li Q; Zhao K
J Thorac Dis; 2018 Sep; 10(9):5328-5338. PubMed ID: 30416780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]